Urology Research & Practice
Invited Review

Alternative therapies in patients with non-muscle invasive bladder cancer


Department of Urology, İstanbul University İstanbul School of Medicine, İstanbul, Turkey


Department of Urology, University of Texas Southwestern Medical Center, Dallas, Texas, USA

Urol Res Pract 2017; 43: 414-424
DOI: 10.5152/tud.2017.64624
Read: 1428 Downloads: 827 Published: 25 July 2019


Bladder cancer (BC) is one of the leading causes of cancer-related deaths worldwide. Despite, the majority of the cases were diagnosed as non-muscle invasive bladder cancer (NMIBC) with favorable prognosis, it has tendency to recur or progress to a higher grade or stage. The first line treatment of patients with NMIBC is transurethral resection with adjuvant therapies primarily intravesical Bacillus Calmette-Guérin (BCG) immunotherapy. However, in a portion of patients whose BCG treatment failed, alternative treatments may be required. Furthermore, intravesical BCG may be contraindicated in or untolerated by a group of patients. For these patients, some treatment options are readily available and a variety of them are currently under clinical investigation. In this review, these alternative therapies have been summarized.



Cite this article as: Şanlı Ö, Lotan Y. Alternative therapies in patients with non-muscle invasive bladder cancer. Turk J Urol 2017; 43(4): 414-24.

EISSN 2980-1478